Oragenics Inc (OGEN) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Oragenics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Oragenics Inc's ROI in the second quarter of 2026?
Oragenics Inc recorded a cumulative net loss of $-10 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -144.23%.
Within the Healthcare sector 680 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 4222, from total ROI ranking in the first quarter of 2026 at 4975.
In an era where neuroscience innovations continually redefine the boundaries of medical science, Oragenics Inc. a nascent trailblazer headquartered in Sarasota, Florida, has marked a pivotal milestone in its quest to revolutionize concussion treatment. On October 8, 2024, the company gleefully announced the successful completion of a landmark study of ONP-002, a novel therapeutic designed for efficacious administration via the nasal cavity, promising rapid intervention post-head injury. As Oragenics, symbolized by the stock exchange ticker (NYSE American: OGEN), consolidates its focus on developing transformative solutions for brain-related health conditions, ONP-002 stands as a testament to its innovative prowess. This vaporous formulation addresses a critical therapeutic gap, offering a potentially swift and efficient means to mitigate the adverse impacts of concussions, an ailment that counts many athletes and accident victims among its sufferers.In an age where time is of the essence, ONP-002 s nasal delivery mechanism is ingeniously conceived. It capitalizes on the proximity of the nasal cavity to the brain, potentially hastening the absorption of therapeutic agents to sites affected by trauma. This could be a game-changer in acute care settings, enabling healthcare providers to ameliorate neuronal damage with an immediacy previously unattainable.
In this most propitious season of scientific endeavor, we find ourselves adorned with delightful tidings from the distinguished halls of Oragenics, Inc. The esteemed purveyors of pharmaceutical innovation have recently proclaimed the resounding success of their neuroprotective compound ONP-002, a potential panacea for the harrowing affliction known as concussion. In a rigorous examination mandated by the venerable Food and Drug Administration, this promising treatment hath emerged victorious, exhibiting no deleterious effects that might rend the very fabric of DNA asunder!With a buoyant heart, one must marvel at the careful scrutiny afforded by the genotoxicity studies, declaring that ONP-002 evinces no inclination towards malign enchancement of cancer-causing agents within the tapestry of one’s genetic constitution. Such news, my dear readers, ignites a flicker of hope in the shadowy realms of neurological maladies that plague Society with increasing frequency. The brilliant minds at Oragenics have thus demonstrated not only the fortitude of their endeavors but also the integrity of their scientific pursuits.Yet, as we raise our goblets in joyous salute to this outstanding advancement in medical research, we must also acknowledge a cloud that looms ominously over Oragenics’ fiscal landscape. In a most lamentable juxtaposition, the esteemed company hath recently reported a cumulative net loss amounting to a staggering $9 million for the fiscal year terminating in the first quarter of the year 2024. Verily, such an amount hath cast a pall over the once-gleaming visions of prosperity, resulting in a most unfortunate return on investment a calamitous -145.73%. What a cruel twist of fate, dear brethren, to have one s scientific triumph shadowed by the burdens of financial adversity! Indeed, the esteemed company finds itself ranked in a rather unbecoming position a descent from 3160 to a most disheartening 3290 in the grand hierarchy of fiscal soundness within the Healthcare sector, where a noteworthy 526 other enterprises boldly claim a higher return on investment.
Oragenics, Inc., a prominent player in the development of intranasal pharmaceuticals for neurological disorders, has recently announced a public offering to raise funds for its ongoing operations. This move comes at a time when the company has faced significant financial challenges, as reflected in its cumulative net loss and negative return on investment (ROI) in the first quarter of 2024. Analyzing the facts and assessing their impact on the company will shed light on its current situation and potential future prospects.
Oragenics, Inc. recently entered into a placement agency agreement to offer 1,100,000 shares of its common stock (or pre-funded warrants) at $1.00 per share. The public offering, expected to close on or about June 26, 2024, is subject to customary closing conditions. This strategic step aims to secure necessary funds for the continued development and commercialization of Oragenics unique intranasal pharmaceuticals.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
